Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer |
Type de publication | Journal Article |
Year of Publication | 2020 |
Auteurs | Delrieu L, Jacquet E, Segura-Ferlay C, Blanc E, Febvey-Combes O, Friedenreich C, Romieu G, Jacot W, Rios M, Heudel P-E, Roemer-Becuwe C, Jouannaud C, Tredan O, Chaigneau L, Arnedos M, Orfeuvre H, Quenel-Tueux N, Jacquin J-P, Ferrero J-M, Moullet I, Abadie-Lacourtoisie S, Penault-Llorca F, Cox D, Bachelot T |
Journal | SCIENTIFIC REPORTS |
Volume | 10 |
Pagination | 10757 |
Date Published | JUL 1 |
Type of Article | Article |
ISSN | 2045-2322 |
Résumé | {Benefits of physical activity are widely demonstrated for early stage cancers but few studies have focused on metastatic disease. The purpose of this study was to determine the impact of physical activity on survival in patients with metastatic breast cancer. We conducted a secondary analysis of the national, multicentric, non-randomized, prospective cohort SNPs to Risk of Metastasis (StoRM) study. The level of physical activity was self-reported at inclusion and divided into three categories of physical activity: light level, moderate level, and vigorous level. Overall, 833 patients (56.2%) completed the physical activity questionnaire at baseline on average physical activity during the previous year: 11.6% had a light level of physical activity, 69.0% achieved moderate levels of physical activity and 19.3% reported vigorous levels of physical activity. After adjustment for confounding, physical activity was not statistically significantly associated with overall survival in the whole population. Subgroup analysis identified that both vigorous and moderate physical activity were associated with statistically significantly improved overall survival compared to light physical activity level only in the HER2 positive subgroup (HR 0.23; 95% CI 0.07-0.70 |
DOI | 10.1038/s41598-020-67431-6 |